The confluence of these several markers associated with the glymphatic system (GFAP, AQP4, LYVE1) and PD (MPO, HOCl-modified epitopes, carbsyn, ntSyn14) argue that MPO oxidants may be an important contributor to the impairment of the glymphatic system in PD. This evidence concerns the gene GFAP and Parkinson disease.